SUBSCRIBE
SUBSCRIBE
News   Policy

U.K. Medicines Advisory Group Rejects GlaxoSmithKline’s (JOBS) Tyverb

July 8, 2008 | 
1 min read

July 8 (Bloomberg) -- GlaxoSmithKline Plc’s oral Tyverb medicine for breast cancer wasn’t recommended for use in the U.K.'s National Health Service, the Financial Times reported.

Regulatory Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
Donald Trump behind a podium
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
Former CytoDyn Officials Found Guilty of Securities Fraud
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac